SK Hynix Shares Fall as Workers Reject Wage Deal 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Tesla Raises Cybertruck Prices by $5,000 in US 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Nvidia Options Price in $280 Billion Earnings Swing 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Trump Buys SpaceX Shares After Record IPO 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Add as a preferred source on Google
MENLO PARK, Calif., May 01, 2018 -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report first quarter financial results and provide a corporate update on May 8, 2018. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Conference Call Information
To participate, dial 1-800-239-9838 from the United States or 1-323-794-2551 internationally approximately 10 minutes before the start of the call. The passcode is 3450659.
A replay will be available through May 22, 2018 at 1-888-203-1112 from the United States and 1-719-457-0820 internationally. The passcode will be 3450659.
About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym® is the company’s first FDA-approved medication. Corcept has a large portfolio of proprietary compounds that modulate the effects of cortisol but not progesterone. Corcept owns extensive United States and foreign intellectual property covering the use of cortisol modulators in the treatment of a wide variety of serious disorders, including Cushing’s syndrome. It also holds composition of matter patents covering its selective cortisol modulators.
CONTACT:
Charles Robb
Chief Financial Officer
Corcept Therapeutics
650-688-8783
[email protected]
www.corcept.com
